NT 0167
Alternative Names: NT-0167Latest Information Update: 28 Jul 2023
At a glance
- Originator Ryvu Therapeutics
- Developer Nodthera
- Class Anti-inflammatories; Small molecules
- Mechanism of Action NLRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in Unknown (PO, Capsule)
- 03 Jul 2021 NodThera terminates a phase I trial in Inflammation (In volunteers) in Australia (PO, Capsule) (ACTRN12620000685910p)
- 02 Oct 2019 Selvita is now called Ryvu Therapeutics